Apogee Therapeutics (APGE) vs. Its Competitors Financial Comparison

Apogee Therapeutics (NASDAQ:APGE) is one of 289 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Apogee Therapeutics to similar companies based on the strength of its dividends, valuation, earnings, analyst recommendations, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Apogee Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	0	0	8	0	3.00
Apogee Therapeutics Competitors	1516	4672	12260	216	2.60

Apogee Therapeutics presently has a consensus target price of $73.00, indicating a potential upside of 94.67%. As a group, “Biological products, except diagnostic” companies have a potential upside of 94.21%. Given Apogee Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Apogee Therapeutics is more favorable than its competitors.

Earnings and Valuation

This table compares Apogee Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Apogee Therapeutics	N/A	-$83.99 million	-7.14
Apogee Therapeutics Competitors	$542.15 million	-$37.52 million	-23.13

Apogee Therapeutics’ competitors have higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Apogee Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-27.14%	-23.24%
Apogee Therapeutics Competitors	-5,257.80%	-217.56%	-45.73%

Institutional & Insider Ownership

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 36.1% of Apogee Therapeutics shares are held by company insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Apogee Therapeutics beats its competitors on 9 of the 12 factors compared.

About Apogee Therapeutics

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.